Measuring fluorescence from surgical suction during glioma surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the effectiveness of a novel device that detects fluorescence from surgical suction waste during glioma surgeries. The study aims to compare the fluorescence detected by this device with the visual evaluation performed by experts using an operating microscope, which utilizes 5-aminolevulinic acid (5-ALA) to enhance tumor visibility. By analyzing the fluorescence feedback, operating videos, and histopathological results, the study seeks to improve tumor resection rates and reduce the chances of local recurrence. A total of 25 patients undergoing surgery for suspected glioma or its recurrence at Kuopio University Hospital will be included in the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Admitted to neurosurgery department for surgical resection of a potential glioma
* Aged 18 years old or older
* Informed consent obtained

Exclusion Criteria:

* Patient belongs to the following vulnerable groups: children, pregnant, prisoners or intellectually disabled,,

Where it's running

• Kuopio University Hospital
  Kuopio, Kuopio, Finland Recruiting

Study contacts

• Principal investigator: Antti-Pekka Elomaa, Docent — Kuopio University Hospital
• Study coordinator: Sami Puustinen, PhD
• Email: sami.puustinen@marginum.com
• Phone: +358442190767

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Taste of hope: testing NRG-103 safety and dosing for adults with high-grade glioma

  This early-phase trial tests whether NRG-103 is safe and tolerable in adults with recurrent or progressive high-grade glioma and looks for early signs it might help.

  Recruiting at 2 sites Phase 1 Neuregen Therapeutics Co., Ltd. · Shanghai and 2 other locations · NCT07710690

• Midline glioma MRI AI model: preoperative molecular subtyping and prognosis

  This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT07608003

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Intratumoral DNX-2401 for High-Grade Pediatric Brain Tumors

  This study tests whether a single injection of DNX-2401 into a pediatric brain tumor can help shrink the tumor and extend survival in kids and young adults with recurrent or refractory high-grade brain tumors.

  Recruiting Phase 2 Clinica Universidad de Navarra, Universidad de Navarra · Utrecht and 1 other locations · NCT07424092

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• Fluorescence-enhanced stereotactic biopsy needle for tumor and vessel detection

  This project will test a biopsy needle fitted with 5-ALA fluorescence, Raman spectroscopy, and ultrasound to see if it can identify tumor tissue and blood vessels in adults with high-grade glioma.

  Recruiting Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Milan · NCT07286903

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.